idiopathic pulmonary fibrosis lung fibrosis
Conditions
Interventions
The intervention of this study consists of a home monitoring program added to
standard care. Control group will receive standard care alone.
The home monitoring program consists of 1) the use of a pr
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: All patients with a diagnosis of IPF according to the ATS 2011 criteria and HRCT/pathology criteria of the Fleischner Society (White paper November 2017), about to start on anti-fibrotic treatment (either nintedanib or pirfenidone) will be invited to participate.
Exclusion criteria
Exclusion criteria: not able to speak, read or write in Dutch, not able to comply with the study protocol according to the judgement of the patient and/or investigator
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| - Costs and cost-effectiveness - Patient expectations and satisfaction with medication - Patient satisfaction with care process - Number of patients who discontinue use of medication - Amount of contacts with healthcare providers and number of visits per patient - FVC decline at 24 weeks - Personal goal of patient defined at start of study - Home monitoring values compared to in hospital values of lung function. - Relation between FVC measurements and PROMs. - Effect of home monitoring on different parameters of (HR)QOL | — |
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the difference in the change in total score of K-BILD (Health-related quality of life) between the home monitoring group and the standard care group at 24 weeks. | — |
Countries
Netherlands
Outcome results
None listed